Menu
Annual · values2026202520242023
Operating Cash Flow-12.28 M USD-8.30 M USD-6.65 M USD-1.85 M USD
Depreciation & Amortization12000 USD183000 USD81000 USD0 USD
Stock-Based Compensation529000 USD1.63 M USD618000 USD0 USD
Capital Expenditures10000 USD14000 USD19000 USD0 USD
Cash Flow from Investing-10000 USD-14000 USD-19000 USD0 USD
Cash Flow from Financing10.16 M USD8.80 M USD14.41 M USD675000 USD
Dividends Paid
Stock Buybacks
Free Cash Flow-12.29 M USD-8.31 M USD-6.67 M USD-1.85 M USD

Autonomix Medical Inc. is a medical device company developing precision nerve-targeted therapies to treat diseases involving the peripheral nervous system. Its first-in-class platform technology features a proprietary catheter-based microchip sensing array that detects and differentiates neural signals with ultra-high sensitivity and on-site data processing, surpassing existing technologies. This enables real-time identification of target nerves, followed by proprietary radio frequency ablation to precisely disable them, and verification of treatment efficacy in a minimally invasive transvascular procedure. Initially focused on pain management for pancreatic cancer patients, the platform addresses unmet needs in chronic pain by offering targeted denervation as an alternative to opioids or invasive methods. With potential applications across cardiology, hypertension, pulmonology, gastroenterology, and interventional pain management, Autonomix Medical Inc. equips physicians with innovative tools for accurate diagnosis and therapy. Headquartered in The Woodlands, Texas, the company advances this breakthrough system protected by a global intellectual property portfolio.